Launch of Co-Promotion for Nasonex
First written in FY2017-Q2. 3 of 9 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2020-Q1.
No other company in this theme has enough history to compare yet.
- FY2020-Q1RestatedAnnual report
「Nasonex Nasal Spray, a metered-dose treatment for allergic rhinitis whose sales were transferred from MSD Co., Ltd. in August of the same year, contributed to sales growth.」
The company continues to disclose Nasonex's contribution to sales growth after the transfer of sales from MSD. - FY2019Cited as achievedAnnual report
「Nasonex Nasal Spray, a metered-dose treatment for allergic rhinitis whose sales began in August 2018」
For Nasonex, the August 2018 sales launch under exclusive domestic sales rights is cited as part of the year's results. - FY2019-Q3RestatedAnnual report
「Sales of Nasonex Nasal Spray, a metered-dose treatment for allergic rhinitis whose domestic sales began in August 2018 under an agreement concerning exclusive domestic sales rights with an affiliate of MSD Co., Ltd., contributed to the expansion of sales of new pharmaceutical products.」
The company continues to disclose that Nasonex began sales in Japan in August 2018 under exclusive domestic sales rights and contributed to its performance with new pharmaceutical products. - FY2019-Q2AdvancedAnnual report
「Kyorin Pharmaceutical Co., Ltd. began sales in August 2018 of Nasonex Nasal Spray, a metered-dose treatment for allergic rhinitis covered by an agreement concerning exclusive domestic sales rights with an affiliate of MSD Co., Ltd., with the aim of expanding its track record with new pharmaceutical products.」
In line with the previous policy of acquiring exclusive sales rights, domestic sales of Nasonex began in August 2018. - FY2019-Q1AdvancedAnnual report
「Domestic company sales agreement (in-licensing) | Contract product: Nasonex Nasal Spray 50 μg | Counterparty: MSD Corporation | Contract year: 2018 | Contract term: Through 31 July 2023 (automatically renewable)」
For Nasonex, the company progressed from the previous co-promotion arrangement to executing a sales agreement based on exclusive sales rights, and disclosed a contract term through 31 July 2023 with automatic renewal provisions. - FY2018ReframedAnnual report
「Kyorin Pharmaceutical Co., Ltd. agreed with MSD Co., Ltd. to acquire exclusive sales rights in Japan for Nasonex and began sales in August 2018.」
The sales model changed from the previous co-promotion arrangement to acquiring exclusive sales rights in Japan, with sales scheduled to begin in August 2018. - FY2017RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. entered into a co-promotion agreement with MSD Co., Ltd. for Nasonex Nasal Spray 50 μg, a metered-dose treatment for allergic rhinitis manufactured and marketed by MSD Co., Ltd., and began promotional activities in November 2016.」
The company continues to list co-promotion of Nasonex as a measure already implemented. - FY2017-Q3AdvancedAnnual report
「Kyorin Pharmaceutical Co., Ltd. entered into a co-promotion agreement with MSD Co., Ltd. for Nasonex Nasal Spray 50 μg, a metered-dose treatment for allergic rhinitis manufactured and marketed by MSD Co., Ltd., and began promotional activities in November 2016.」
Following the execution of the agreement in September 2016, co-promotion of Nasonex began in November 2016. - FY2017-Q2First statedAnnual report
「In September 2016, KYORIN Pharmaceutical Co.,Ltd. entered into a co-promotion agreement with MSD for Nasonex Nasal Spray 50 μg, an aerosolized treatment for allergic rhinitis manufactured and marketed by MSD, and agreed to begin joint promotion in November of that year.」
Following execution of the agreement with MSD, a co-promotion initiative for Nasonex was launched in November 2016.